FDA approves GSK's Utebzi, an oral antibiotic for complicated urinary tract infections with few alternatives
Tebipenem pivoxil was non-inferior to intravenous imipenem-cilastatin in hospitalized patients, at 58.5% against 60.2% on the composite response.